很多人第一次认识我们，是通过一篇微信公众号文章、一份白皮书、一组行业深度稿件，或一次行业大会。也 有不少企业在合作之后才逐渐意识到： 思宇是帮忙宣传的平台，更是一家长期站在产业视角、理解技术与临床逻辑的内容与研究型机构。 我们成立于2016年底，已度过9岁生日。现计划在2026年内扩充团队，因此发布本招聘说明。为了找到真正合 适的人，我们并不着急，也欢迎长期关注。 一、我们在做什么？ 思宇 MedTech 面向医疗科技行业的专业人群，核心工作包括： 主要读者与合作对象包括： 二、需要应聘者做什么？ 围绕医疗科技产品、企业与行业开展内容工作，包括但不限于： 为医疗器械企业进行内容策划 参与年度传播主题、系列文章与关键节点内容的策划与拆解 希望具备以下特质和习惯： 补充说明： 教育背景以工科/医/药相关专业为主，硕士研究生；目前不招聘本科生，也暂不招聘博士。团队为全女性成 员。 四、我们如何一起工作？ 对企业原始素材进行专业化改写与重构 将研发进展、产品资料、临床信息等，转化为逻辑清晰、表达克制、可被行业理解的内容 参与白皮书、行业报告等中长期项目 包括资料调研、结构梳理、章节撰写或协作，理解一个赛道如何被系统性 ...

Core Viewpoint - Johnson & Johnson MedTech is transitioning its global business operations from a regional model to a business unit (BU) led structure starting January 1, 2026, to enhance competitiveness and value creation for customers and patients [1][4][10] Group 1: Reasons for Restructuring - The global medical device industry is undergoing significant changes, with advancements in precision medicine, minimally invasive surgery, digital health, robotics, and interventional devices, necessitating faster response times and localized compliance [3] - The traditional regional operational model of large medical device companies is seen as cumbersome and slow, hindering rapid innovation and global promotion [3] Group 2: Strategic Significance of the Restructuring - The divestiture of the orthopedic business DePuy Synthes, which previously accounted for nearly 30% of global MedTech revenue, allows the company to focus on high-growth areas such as cardiovascular, surgical, vision care, and interventional devices [4][10] - The new BU-led structure will enable faster resource allocation, enhance specialized operational capabilities, and improve product commercialization efficiency [4][9] Group 3: New Structural Arrangements - Each business unit will be responsible for its global business performance, managing everything from strategic planning to commercial execution [8] - Supply chain management will be centralized to improve global procurement and distribution efficiency [8] - Functional support departments will be restructured to align with the new BU-led operational model [8] Group 4: Expected Outcomes - The BU-led model will enhance operational efficiency and responsiveness, granting higher autonomy and decision-making flexibility to business units [9] - Resource allocation will become more concentrated and specialized, focusing on high-growth sectors [9] - Accelerated product innovation and global commercialization will be facilitated through closed-loop management from product design to global market launch [9] Group 5: Industry and Market Implications - This restructuring may serve as a trendsetter for other established medical device companies to adapt their structures in response to rapid technological and market changes [11] - The BU-led approach could shorten new product launch cycles, improving the accessibility of innovative devices and treatment solutions for hospitals and patients [11] - Increased competition dynamics may emerge in high-end interventional, digital health, and surgical device sectors, posing challenges for smaller innovative companies and new entrants [11]

Core Viewpoint - The stock price of Haohai Biological Technology Co., Ltd. has experienced a decline of 17.01% year-to-date, with a recent drop of 2.00% on November 26, 2023, indicating potential challenges in the company's market performance [1]. Financial Performance - For the period from January to September 2025, Haohai Biological reported a revenue of 1.899 billion yuan, a year-on-year decrease of 8.47%, and a net profit attributable to shareholders of 305 million yuan, down 10.63% compared to the previous year [2]. - Cumulatively, the company has distributed a total of 891 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Haohai Biological increased by 7.44% to 8,388, with an average of 0 circulating shares per shareholder [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 5.6048 million shares, an increase of 2.617 million shares from the previous period [3]. Market Activity - On November 26, 2023, Haohai Biological's stock traded at 49.46 yuan per share, with a total market capitalization of 11.503 billion yuan. The trading volume was 38.4425 million yuan, with a turnover rate of 0.40% [1]. - The net outflow of main funds was 1.5809 million yuan, with significant selling activity observed [1].

Core Viewpoint - The stock price of Haohai Biological Technology Co., Ltd. has experienced a decline of 15.47% year-to-date, with a slight recovery observed on November 25, where it rose by 2.13% to reach 50.38 CNY per share, indicating potential market interest despite recent downturns [2][1]. Company Overview - Haohai Biological Technology, established on January 24, 2007, and listed on October 30, 2019, is located in Shanghai and specializes in the research, production, and sales of medical devices and pharmaceuticals [2]. - The company's revenue composition includes: 44.12% from medical beauty and wound care products, 28.18% from ophthalmic products, 17.39% from orthopedic products, 8.46% from anti-adhesion and hemostatic products, and 1.86% from other products [2]. Financial Performance - For the period from January to September 2025, Haohai Biological reported a revenue of 1.899 billion CNY, reflecting a year-on-year decrease of 8.47%, while the net profit attributable to shareholders was 305 million CNY, down 10.63% year-on-year [2]. - The company has distributed a total of 891 million CNY in dividends since its A-share listing, with 557 million CNY distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 7.44% to 8,388, with an average of 0 shares held in circulation per shareholder [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 5.6048 million shares, an increase of 2.617 million shares compared to the previous period [3]. Market Activity - On November 25, the stock saw a trading volume of 31.1529 million CNY, with a turnover rate of 0.32%, and a net inflow of main funds amounting to 1.7261 million CNY [1].

Core Viewpoint - Zhongtai International has set the target price for Weigao Co., Ltd. (01066) at HKD 5.94, maintaining a "Buy" rating while adjusting revenue forecasts for 2025-2027 down by 5.2%, 5.9%, and 6.0% respectively, and net profit forecasts down by 6.4%, 5.4%, and 5.8%, although both revenue and profit are still expected to achieve positive growth [1] Group 1 - The company achieved positive revenue growth in the first three quarters of 2025, with a 2.6% year-on-year increase in Q3 revenue to RMB 3.26 billion, leading to a total revenue increase of 0.9% to approximately RMB 9.81 billion for the first three quarters, slightly below expectations [2] - The medical device and pharmaceutical packaging segments were impacted by the centralized procurement of low-value consumables and syringe procurement, but sales of orthopedic products are expected to improve in the second half of the year, while sales of interventional and blood management products continue to grow rapidly [2] Group 2 - The pharmaceutical packaging business experienced a slight decline in revenue due to centralized procurement of syringes, with a year-on-year decrease of 0.1% in the first half and only low single-digit growth in Q3; revenue forecasts for the pharmaceutical packaging business for 2025-2027 have been adjusted down by 8.9%, 13.5%, and 13.4% respectively [3] - The impact of centralized procurement on the medical device segment has largely been reflected, with the expectation that sales revenue will gradually recover starting in 2026 as the nationwide implementation of low-value consumables procurement has been completed [4] Group 3 - The orthopedic business is expected to recover in the second half of the year as the company shifts its sales model from direct sales to distribution in 2025; after a 1.6% year-on-year decline in sales revenue in the first half due to the adjustment period with distributors, Q3 sales revenue for this segment increased by approximately 10% [5]

Core Viewpoint - Zhongtai International has set a target price of HKD 5.94 for Weigao Group (01066) and assigned an "Accumulate" rating, while adjusting revenue and net profit forecasts for 2025-2027 downwards, yet still expecting positive growth in both metrics [1] Group 1: Revenue Performance - The company achieved a year-on-year revenue increase of 2.6% to RMB 3.26 billion in Q3 2025, contributing to a total revenue of approximately RMB 9.81 billion for the first three quarters, reflecting a slight year-on-year growth of 0.9% [1] - Despite slightly lower-than-expected revenue, all segments are expected to show positive growth, with orthopedic product sales improving in the second half of the year [1] Group 2: Impact of Price Collection - The drug packaging business experienced a slight revenue decline of 0.1% year-on-year in the first half of the year due to the impact of centralized procurement of syringe products, with only low single-digit growth in Q3 [2] - The revenue forecasts for the drug packaging business for 2025-2027 have been adjusted downwards by 8.9%, 13.5%, and 13.4% respectively due to ongoing impacts from centralized procurement [2] Group 3: Medical Device Sector - The medical device sector has been affected by centralized procurement of low-value consumables since the second half of 2022, leading to revenue impacts starting in 2023 [3] - However, as the centralized procurement has been fully implemented nationwide, the price reduction effects are expected to be largely reflected, with a gradual recovery in sales revenue anticipated from 2026 [3] Group 4: Orthopedic Business Recovery - To boost orthopedic product sales, the company plans to shift its sales model from direct sales to distribution in 2025, which initially led to a 1.6% year-on-year decline in sales revenue during the first half of the year due to a transition period with distributors [4] - Sales revenue for the orthopedic segment improved by approximately 10% year-on-year in Q3, indicating a recovery in the second half of the year [4]

Core Viewpoint - The stock price of Haohai Biological Technology Co., Ltd. has shown fluctuations, with a recent increase of 2.01% on November 10, 2023, despite a year-to-date decline of 13.94% [1][2]. Company Overview - Haohai Biological Technology, established on January 24, 2007, and listed on October 30, 2019, is located in Shanghai and specializes in the research, production, and sales of medical devices and pharmaceuticals [2]. - The company's main revenue sources are: medical beauty and wound care products (44.12%), ophthalmic products (28.18%), orthopedic products (17.39%), anti-adhesion and hemostatic products (8.46%), and other products (1.86%) [2]. Financial Performance - For the period from January to September 2025, Haohai Biological reported a revenue of 1.899 billion yuan, a year-on-year decrease of 8.47%, and a net profit attributable to shareholders of 305 million yuan, down 10.63% year-on-year [2]. - The company has distributed a total of 891 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 7.44% to 8,388, with an average of 0 shares per shareholder [2]. - Hong Kong Central Clearing Limited is the seventh largest circulating shareholder, holding 5.6048 million shares, an increase of 2.617 million shares from the previous period [3]. Market Activity - On November 10, 2023, the stock traded at 51.29 yuan per share, with a total market capitalization of 11.929 billion yuan and a trading volume of 28.2676 million yuan [1]. - The net inflow of main funds was 2.4664 million yuan, with large orders accounting for 20.66% of purchases and 11.93% of sales [1].

Core Viewpoint - Hunan Jingfeng Pharmaceutical Co., Ltd. (*ST Jingfeng) has shown a reverse trend in performance improvement, with a net profit of 11.9975 million yuan in Q3 2025, representing a year-on-year increase of 23.91% [1] Group 1: Debt Restructuring and Financial Improvement - The orderly progress of the restructuring process has injected vital energy into *ST Jingfeng, significantly alleviating debt pressure [2] - The company has reached agreements with bondholders to effectively reduce financial costs, improving the quality of financial statements [2] - Capital injection and debt waivers have collectively supplemented working capital and optimized the asset-liability structure, creating conditions for the recovery of core business [2] Group 2: Asset Optimization and Cash Flow Improvement - *ST Jingfeng has optimized resource allocation through asset disposals, leading to a significant improvement in cash flow [3] - The company has implemented cost reduction and efficiency enhancement measures, improving the efficiency of fund utilization [3] - By divesting loss-making subsidiaries and focusing on core product lines, the company has laid a foundation for improved operational efficiency [3] Group 3: Market Expansion and R&D Support - The company's core products have achieved volume growth through successful bids in centralized procurement, becoming a key support for revenue growth [4] - The collaboration with Shijiazhuang Pharmaceutical Group is expected to activate the value of existing assets, providing a rebirth opportunity for *ST Jingfeng [4] - Short-term financial improvements are driving performance rebounds, while long-term sustainability will depend on the volume growth of core products and R&D conversion efficiency [4]

Core Viewpoint - Northeast Securities has given a "buy" rating to Weigao Group (01066) following its successful acquisition of MDSAP certification, which will facilitate the international expansion of its products [1] Group 1: Company Performance and Projections - The company is a leading provider of comprehensive medical system solutions in China, focusing on platformization, internationalization, and digitalization to maintain its market leadership [1] - Revenue projections for Weigao Group are estimated at 135.41 billion, 149.60 billion, and 163.01 billion yuan for the years 2025 to 2027, with net profits of 20.76 billion, 23.57 billion, and 26.05 billion yuan respectively, corresponding to PE ratios of 12X, 10X, and 9X [1] Group 2: MDSAP Certification and Product Development - The MDSAP certification is recognized by regulatory bodies in the US, Australia, Brazil, Canada, and Japan, allowing manufacturers to streamline their quality management system audits, thus saving time and resources [2] - The company plans to enhance its product matrix by transitioning from low-cost to high-cost/specialized products, with over 100 new products expected to be approved in the next three years [2] - The orthopedic segment will focus on new materials, regenerative rehabilitation, smart assistance, and 3D printing, particularly in minimally invasive spine and pain management [2] - The company is also expanding its blood management segment, with a projected production capacity of over 100 million blood bags by 2025 and an additional 20 million overseas capacity expected next year [2] Group 3: International Revenue and Acquisitions - In the first half of 2025, the company achieved overseas revenue of 16.24 billion yuan, a year-on-year increase of 3.98%, accounting for 24.44% of total revenue, with significant growth in the US and EMEA regions [3] - Recent acquisitions include Argon, a US interventional device manufacturer, GHC Healthcare, a medical device distributor, and Radsource, a blood irradiation device manufacturer, which have been integrated to enhance synergies [3]

Core Viewpoint - Weigao Co., Ltd. has successfully obtained the MDSAP certification, enhancing its international market expansion capabilities and solidifying its leading position in the medical system solutions sector [1][2]. Financial Projections - The company is projected to achieve revenues of 135.41 billion, 149.60 billion, and 163.01 billion CNY for the years 2025 to 2027, with corresponding net profits of 20.76 billion, 23.57 billion, and 26.05 billion CNY, resulting in PE ratios of 12X, 10X, and 9X respectively [1]. MDSAP Certification Impact - The MDSAP certification, recognized by regulatory bodies in the US, Australia, Brazil, Canada, and Japan, allows manufacturers to streamline their quality management system audits, significantly reducing time and resource costs associated with multiple country certifications [2]. Product Development and Market Strategy - The company is focusing on enhancing its product matrix by transitioning from low-cost to high-cost/specialized products, with plans to approve over 100 new products in the next three years [2]. - In the orthopedic sector, the company is expanding into new materials, regenerative rehabilitation, smart assistance, and 3D printing, particularly in minimally invasive spine and pain management areas [2]. - The interventional segment has plans to shift some main products to mainland production, with upcoming product launches and academic seminars for Cleaner Vac [2]. - The pharmaceutical packaging segment is developing new production lines for pre-filled syringes and automatic injection pens, expected to commence production in 2026 [2]. - The blood management segment anticipates exceeding a total production capacity of 100 million blood bags by 2025, with an additional 20 million sets of overseas capacity planned for next year [2]. International Revenue Performance - In the first half of 2025, the company reported overseas revenues of 16.24 billion CNY, a year-on-year increase of 3.98%, accounting for 24.44% of total revenue, with significant growth in the US and EMEA regions [3]. - The company has made strategic acquisitions in recent years, including Argon, GHC Healthcare, and Rad Source, to enhance its overseas platform integration and realize synergies [3].